{
    "organizations": [],
    "uuid": "084e86b19c0e25a972641c1c20c33aa74e51fd4a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-takes-steps-to-advance-develop/brief-fda-takes-steps-to-advance-development-of-opioid-use-disorder-treatment-idUSFWN1RX0OR",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Takes Steps To Advance Development Of Opioid Use Disorder Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20 (Reuters) - U.S. FDA:\n* U.S. FDA TAKES NEW STEPS TO ADVANCE THE DEVELOPMENT OF INNOVATIVE PRODUCTS FOR TREATING OPIOID USE DISORDER\n* U.S. FDA - FIRST GUIDANCE EXPLAINS FDA’S THINKING ON ISSUES RELEVANT TO SUSTAINED-RELEASE “DEPOT” BUPRENORPHINE PRODUCTS STUDY\n* FDA - WILL ISSUE ADDITIONAL GUIDANCE ON DEVELOPING NOVEL CLINICAL ENDPOINTS WHICH FORM BASIS OF MEDICATION-ASSISTED TREATMENT PRODUCT APPROVALS Source text : ( bit.ly/2HgARje )\n ",
    "published": "2018-04-20T22:13:00.000+03:00",
    "crawled": "2018-04-21T18:11:09.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "fda",
        "fda",
        "take",
        "new",
        "step",
        "advance",
        "development",
        "innovative",
        "product",
        "treating",
        "opioid",
        "use",
        "disorder",
        "fda",
        "first",
        "guidance",
        "explains",
        "fda",
        "thinking",
        "issue",
        "relevant",
        "depot",
        "buprenorphine",
        "product",
        "study",
        "fda",
        "issue",
        "additional",
        "guidance",
        "developing",
        "novel",
        "clinical",
        "endpoint",
        "form",
        "basis",
        "treatment",
        "product",
        "approval",
        "source",
        "text"
    ]
}